We also market branded Ampyra (dalfampridine) Extended Release Tablets, 10 mg. Net revenue for Inbrija was $24.2 million for the year ended December 31, 2020. This payment was recorded as milestone revenue in the third quarter. The COVID-19 pandemic has caused significant disruptions in the healthcare industry. Inbrija is for as needed use and utilizes our ARCUS platform for inhaled therapeutics. 8226; increased eye pressure in patients with glaucoma. This was demonstrated by an increase in walking speed. Fampyra has been approved in a number of countries across Europe, Asia and the Americas. We will vigorously defend our intellectual property rights. We completed these studies and timely submitted the results to the FDA. Civitas is required to use commercially reasonable efforts to develop ARCUS products. Any such interruptions in their ability to manufacture Inbrija would harm our business. Transition to a new inhaler supplier would be a lengthy and complex process. Ampyra/aminopyridines There are no patents listed in the Orange Book for Ampyra. Apokyn was approved for this use in the U.S. in 2004 and in Europe in 1993. Inbrija may face competition from therapies that can limit the occurrence of OFF periods. This therapy, known as Duopa, has been approved by the FDA and is approved in the EU. Many of these corticosteroids are available generically. This is known as a Special Protocol Assessment, or SPA. These fees could be significant. Instead, the FDA must make a separate finding of "interchangeability." The risks and uncertainties described below are not the only ones we face. The same risks apply to our other marketed products, such as Ampyra. In some cases, the penalties for failure to comply with these requirements are unclear. As of December 31, 2020, we had approximately $162.1 million of U.S. Federal NOLs.